Unjha Formulations Q1 Results FY27: PAT at Rs 16 Lakh for June 2026 Quarter

The Unjha Formulations Q1 results FY27 show standalone revenue of Rs 3 Cr for the quarter ended 30 June 2026, -8.98% year on year from Rs 3 Cr in Q1 FY26, as Unjha Formulations reported its numbers on 4 August 2026. Unjha Formulations posted pat of Rs 0.16 Cr for the quarter, against Rs 0.39 Cr in Q1 FY26, a change of -59.76%. Shares traded around Rs 28.45 on the NSE, down 1.04% on the day.

The June 2026 quarter played out against a broadly stable macro backdrop, contained inflation, a supportive monsoon outlook, and resilient domestic consumption, though global uncertainty around tariffs and commodity prices kept sector-level variability elevated. Against that backdrop, the Unjha Formulations Q1 results FY27 give investors the first hard data point for FY27. This article breaks down what happened at the revenue, gross profit, and net profit line, what the numbers mean for the full year, and what questions investors should be asking before making any portfolio decision.

Click Here – Get Free Investment Predictions

Unjha Formulations Q1 results FY27 Financial Highlights

All figures are standalone numbers in Rs Crore as reported by Unjha Formulations for Q1 FY27 (April to June 2026). The table compares them against the same quarter in FY26.

Metric	Q1 FY27 (Jun 2026)	Q1 FY26 (Jun 2025)	YoY Change
Revenue	Rs 3 Cr	Rs 3 Cr	-8.98%
Gross Profit	Rs 0.16 Cr	Rs 0.39 Cr	-59.46%
Gross Profit Margin	5.3%	13.0%	-7.7 pts
Net Profit (PAT)	Rs 0.16 Cr	Rs 0.39 Cr	-59.76%
Net Profit Margin	5.3%	13.0%	-7.7 pts

Unjha Formulations Q1 results FY27 Performance Analysis

Revenue contracted this quarter, the most visible headwind in the numbers. Unjha Formulations reported Rs 3 Cr, down -8.98% from Rs 3 Cr in Q1 FY26. Investors will want to understand whether this is a cyclical correction, a volume/mix issue, or something more structural.

Margin pressure was visible in the Unjha Formulations Q1 results FY27. Gross profit moved -59.46% to Rs 0.16 Cr (5.3% margin) from Rs 0.39 Cr in Q1 FY26, growing slower than revenue or contracting outright. Input costs or pricing pressure appear to be the key culprits.

Unjha Formulations saw its net profit (PAT) contract this quarter. Rs 0.16 Cr compares with Rs 0.39 Cr a year earlier, a fall of -59.76%. Margin compression is the story here, and investors will want a clear path to recovery before re-engaging.

Check the Univest Screener for Live Data

Unjha Formulations Q1 results FY27: Key Business Factors

1. Revenue: What Drove the Quarter

Unjha Formulations reported revenue of Rs 3 Cr for the June 2026 quarter, down -8.98% from Rs 3 Cr in Q1 FY26. A revenue decline in the broader market can reflect channel destocking, a strategic exit from low-margin business, or genuine demand weakness. Management's explanation on the earnings call will determine how investors reprice the stock. Investors should distinguish between structural decline and a one-quarter correction before drawing conclusions from the Unjha Formulations Q1 results FY27.

2. Gross Profit and Margin Trends

Gross margin contracted to 5.3% from 13.0% a year ago, a compression of 7.7 percentage points. In the broader market, input cost movements, demand cyclicality and competitive intensity are the primary margin levers. The contraction in the Unjha Formulations Q1 results FY27 suggests these headwinds were not fully offset by pricing or operating efficiency in the June quarter. Management's guidance on recovery will be the key input for FY27 earnings estimates.

3. Net Profit and Earnings Quality

Unjha Formulations posted pat of Rs 0.16 Cr for the June 2026 quarter, against Rs 0.39 Cr in Q1 FY26, a change of -59.76%. This bottom line figure is what drives earnings per share and, ultimately, the P/E multiple at which the stock trades. Analysts will now update their FY27 EPS estimates using this Q1 run rate, adjusted for any seasonal factors and guidance management provides on the earnings call.

Unjha Formulations Q1 results FY27 vs Analyst Expectations

Analyst estimates for the Unjha Formulations Q1 results FY27 varied ahead of the announcement. The actual revenue of Rs 3 Cr and PAT of Rs 0.16 Cr now set the benchmark against which FY27 consensus estimates will be revised. When a company beats on both revenue and profit, the stock typically sees buying in the first post-result session. A miss on both tends to trigger selling and downgrades. A mixed print stays range-bound until the earnings call provides clarity. Investors tracking Unjha Formulations should check live analyst verdict updates on the Univest Screener alongside the stock price movement to contextualise the post-result market reaction.

Unjha Formulations Dividend Update

No specific dividend announcement was confirmed as part of the Unjha Formulations Q1 results FY27 snapshot. Most companies declare dividends at the annual board meeting rather than with quarterly results. Investors tracking Unjha Formulations for its dividend yield should check the official NSE or BSE exchange filing, or the Univest Screener, for the latest record date and payout details.

Unjha Formulations Outlook After Q1 results FY27

The Unjha Formulations Q1 results FY27 establish the Q1 FY27 baseline for revenue at Rs 3 Cr and PAT at Rs 0.16 Cr. Whether FY27 ends up as a year of acceleration depends on two variables: whether the decline in revenue sustains through Q2 to Q4, and whether margin trends improve, stabilise, or deteriorate relative to this quarter's gross profit margin of 5.3% . Management guidance on the earnings call will be the single most important datapoint for updating FY27 forecasts. Investors should also track macroeconomic inputs relevant to the broader market through the rest of the year.

The Q1 FY27 print gives investors a base to work from, but one quarter is rarely enough to conclude a trend. The key follow-up question for Unjha Formulations is whether the Q1 performance was driven by seasonal tailwinds or something more durable. Q2 FY27 results, due around October 2026, will be the first test of that. Investors should also watch for any corporate actions, debt announcements, or management changes in the interim.

Should You Buy Unjha Formulations After the Q1 results FY27?

The question most investors ask after any quarterly result is whether it changes the investment case. The Unjha Formulations Q1 results FY27 show revenue of Rs 3 Cr, gross profit of Rs 0.16 Cr, and PAT of Rs 0.16 Cr. Whether these numbers justify buying, holding, or selling depends on the price the stock is trading at (Rs 28.45 at the time of this result), the FY27 consensus earnings estimate, and whether this Q1 run rate is sustainable for the remaining three quarters. Investors should check the P/E, P/B, and EV/EBITDA multiples on the Univest Screener against sector peers before deciding. This article is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered investment advisor before making any investment decision.

Unjha Formulations Share Price After the Q1 results FY27

Unjha Formulations shares traded at Rs 28.45 on the NSE, down 1.04% on the day the Unjha Formulations Q1 results FY27 were in focus. Post-result price moves are often driven by event-driven traders who have built positions ahead of the result and unwind them regardless of outcome. Investors should look past the first-session move and focus on whether the fundamental trend in revenue and earnings has changed. The 52 week high, 52 week low, and technical support levels for Unjha Formulations are available on the Univest Screener for investors who want to time their entry or exit.

Download the Univest iOS App or Univest Android App to track Unjha Formulations live share price and upcoming quarterly results.

Key Risks to Track After the Unjha Formulations Q1 results FY27

Investors should weigh these risks carefully before acting on the Q1 data.

1. Sector and Margin Risk

Unjha Formulations operates in the broader market, which is exposed to input cost movements, demand cyclicality and competitive intensity. A reversal of the trends visible in the Unjha Formulations Q1 results FY27, particularly on the gross profit margin, could put the full-year FY27 earnings estimate at risk.

2. Single-Quarter vs Trend Risk

A single quarterly result can be distorted by working capital cycles, timing of receivables, or one-off costs and reversals that do not repeat. The Unjha Formulations Q1 results FY27 should be read alongside Q2 data before drawing firm conclusions.

3. Macro and External Risk

Macro factors including RBI rate decisions, INR/USD movements, input commodity prices, and rural versus urban demand mix can shift the environment in the broader market faster than company-level actions can compensate for.

Conclusion

The Unjha Formulations Q1 results FY27 show standalone revenue of Rs 3 Cr (-8.98% year on year) and PAT of Rs 0.16 Cr (versus Rs 0.39 Cr in Q1 FY26). Gross profit came in at Rs 0.16 Cr at a margin of 5.3%, declining from Rs 0.39 Cr a year earlier. A revenue decline and pressure on the bottom line were the two key themes of the quarter. Investors tracking Unjha Formulations should use the Unjha Formulations Q1 results FY27 as the baseline and watch Q2 FY27 results, due around October 2026, as the first confirmation of whether these trends are durable. Always consult a SEBI-registered advisor before acting on any quarterly result.

Frequently Asked Questions on Unjha Formulations Q1 results FY27

What were the Unjha Formulations Q1 results FY27?

Ans. Unjha Formulations reported revenue of Rs 3 Cr (-8.98% YoY) and PAT of Rs 0.16 Cr for Q1 FY27 (quarter ended 30 June 2026), against Rs 0.39 Cr in Q1 FY26.

What is the PAT in the Unjha Formulations Q1 results FY27?

Ans. PAT in the Unjha Formulations Q1 results FY27 stood at Rs 0.16 Cr, compared with Rs 0.39 Cr in Q1 FY26, a change of -59.76%.

What was the revenue in the Unjha Formulations Q1 results FY27?

Ans. Revenue in the Unjha Formulations Q1 results FY27 was Rs 3 Cr, a change of -8.98% from Rs 3 Cr in Q1 FY26.

What was the gross profit in the Unjha Formulations Q1 results FY27?

Ans. Gross profit in the Unjha Formulations Q1 results FY27 was Rs 0.16 Cr (5.3% margin), compared with Rs 0.39 Cr in Q1 FY26, a change of -59.46%.

Did Unjha Formulations declare a dividend with the Q1 results FY27?

Ans. No dividend was confirmed as part of the Unjha Formulations Q1 results FY27 snapshot. Check the NSE or BSE exchange filing for the latest dividend announcement from Unjha Formulations.

What is the outlook for Unjha Formulations after Q1 results FY27?

Ans. Following the Unjha Formulations Q1 results FY27, analysts will track whether the decline in revenue and decline in profit continue into Q2 FY27 (September quarter), along with margin trends and management guidance.

Is Unjha Formulations a good buy after Q1 results FY27?

Ans. The Unjha Formulations Q1 results FY27 show revenue of Rs 3 Cr and PAT of Rs 0.16 Cr. Investment decisions should be based on valuation relative to earnings trajectory, not a single quarter. Consult a SEBI-registered advisor before investing.